^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TPI 287

    i
    Other names: TPI 287, ARC 100, NBT 287, TPI-287, TPI287, ARC100, ARC-100, NBT-287, NBT287
    Associations

    News

    Trials
    Company:
    CNS Pharma, Cortice Biosci
    Drug class:
    Microtubule inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost2years
    The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo. (PubMed, Cancer Chemother Pharmacol)
    Results suggest that apoptosis is the dominant mechanism of potentiation of GBM growth inhibition by alisertib + TPI 287, in part through effects on Bcl-2 family proteins, providing a rationale for further laboratory testing of an AURKA inhibitor plus TPI 287 as a potential therapy against GBM.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • ANXA5 (Annexin A5)
    |
    alisertib (MLN8237) • TPI 287